PHARMACOGENETICS OF PRO 12ALA PPAR-GAMMA-2

PRO 12ALA PPAR-GAMMA-2 的药物遗传学

• 批准号: 7376930
• 负责人: ALAN R. SHULDINER
• 金额: $ 0.59万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376930
• 关键词: PHARMACOGENETICS; PRO; 12ALA; PPAR; GAMMA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this protocol is to determine why some individuals do not respond well to thiazolidinediones, a class of antidiabetic drugs. These drugs work by improving the sensitivity of the body to insulin. Subjects will be recruited on the basis of their genotype, as it is believed that a particular variant (Pro 12Ala PPAR-gamma-2) may cause a blunted response to these drugs. Subjects with impaired glucose tolerance (a precursor of diabetes) will be recruited and treated with rosiglitazone, a thiazolidinedione. Insulin sensitivity will be tested before and after a 12 week treatment with rosiglitazone, both in terms of glucose uptake an inhibition of lipolysis (fat breakdown). Likewise, gene expression in fat and muscle will be studies before and after treatment. The protocol concludes with a 12 week didactic weight management program.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。该方案的目的是确定为什么有些人对噻唑烷二酮类（一类抗糖尿病药物）反应不佳。这些药物通过提高身体对胰岛素的敏感性来发挥作用。将根据受试者的基因型招募受试者，因为据信特定变体（Pro 12Ala PPAR-gamma-2）可能会导致对这些药物的反应减弱。将招募糖耐量受损（糖尿病的前兆）的受试者并用罗格列酮（一种噻唑烷二酮）进行治疗。将在罗格列酮治疗 12 周之前和之后测试胰岛素敏感性，包括葡萄糖摄取和脂解抑制（脂肪分解）。同样，将在治疗前后研究脂肪和肌肉中的基因表达。该方案以为期 12 周的体重管理教学计划结束。